Jing Zhang

Jing Zhang

Auto-generated profile, based on publicly available information

Jing Zhang

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HDHuan Dong
Huan Dong
JCJia Chen
Jia Chen
JZJing Zhang
Jing Zhang
FXFeng Xue
Feng Xue
HLHuiyuan Li
Huiyuan Li
LZLei Zhang
Lei Zhang
Purpose: Triple-negative (TN) essential thrombocytopenia (ET) is characterized by the absence of driver mutations while retaining histologic and phenotypic characteristics sufficient for an ET diagnosis. Our understanding of TN-ET and its platelet activation remains incomplete. We carried out a large-scale multicenter clinical analysis to analyze the clinical and molecular characteristics and thrombotic complications of TN-ET. We also related the above characteristics to platelet activation to further explore the thrombosis mechanism of TN-ET. Experimental Design: A retrospective multicenter study was conducted on 138 patients with TN-ET and 759 patients with ET with driver mutations from March 1, 2012 to December 1, 2021. The clinical and molecular characteristics of the patients with TN-ET were summarized. Additionally, platelet activation, apoptosis, and reactive oxygen species (ROS) levels were analyzed in 73 patients with TN-ET from this cohort and compared with 41 age- and sex-matched healthy donors. Results: Compared with patients with the JAK2V617F mutation, those with TN mutation were younger (P < 0.001) and exhibited fewer thrombotic events before diagnosis (P < 0.001) and during follow-up (P = 0.039). Patients with TN mutation also presented with significantly reduced CD62P expression in platelets (P = 0.031), slightly reduced calcium concentration in platelets (P = 0.063), increased mitochondrial membrane potential (P = 0.011), reduced phosphatidylserine exposure (P = 0.015), reduced levels of ROS (P = 0.043) and MitoSOX in platelets (P = 0.047). Conclusions: In comparison with JAK2V617F-mutated ET, TN-ET is associated with lower platelet ROS levels, which leads to reduced platelet activation and consequently a lower risk of thrombosis.

2 December 2024
Verified
Other
Open access
HDHuan Dong
Huan Dong
JCJia Chen
Jia Chen
JZJing Zhang
Jing Zhang
FXFeng Xue
Feng Xue
HLHuiyuan Li
Huiyuan Li
LZLei Zhang
Lei Zhang
Supplementary Figure S2. Platelet CD62P expression and phosphatidylserine exposure of TN-ET platelets after ROS inhibition.

2 December 2024
Verified
Other
Open access
HDHuan Dong
Huan Dong
JCJia Chen
Jia Chen
JZJing Zhang
Jing Zhang
FXFeng Xue
Feng Xue
HLHuiyuan Li
Huiyuan Li
LZLei Zhang
Lei Zhang
Purpose:Triple-negative (TN) essential thrombocytopenia (ET) is characterized by the absence of driver mutations while retaining histologic and phenotypic characteristics sufficient for an ET diagnosis. Our understanding of TN-ET and its platelet activation remains incomplete. We carried out a large-scale multicenter clinical analysis to analyze the clinical and molecular characteristics and thrombotic complications of TN-ET. We also related the above characteristics to platelet activation to further explore the thrombosis mechanism of TN-ET.Experimental Design:A retrospective multicenter study was conducted on 138 patients with TN-ET and 759 patients with ET with driver mutations from March 1, 2012 to December 1, 2021. The clinical and molecular characteristics of the patients with TN-ET were summarized. Additionally, platelet activation, apoptosis, and reactive oxygen species (ROS) levels were analyzed in 73 patients with TN-ET from this cohort and compared with 41 age- and sex-matched healthy donors.Results:Compared with patients with the JAK2V617F mutation, those with TN mutation were younger (P < 0.001) and exhibited fewer thrombotic events before diagnosis (P < 0.001) and during follow-up (P = 0.039). Patients with TN mutation also presented with significantly reduced CD62P expression in platelets (P = 0.031), slightly reduced calcium concentration in platelets (P = 0.063), increased mitochondrial membrane potential (P = 0.011), reduced phosphatidylserine exposure (P = 0.015), reduced levels of ROS (P = 0.043) and MitoSOX in platelets (P = 0.047).Conclusions:In comparison with JAK2V617F-mutated ET, TN-ET is associated with lower platelet ROS levels, which leads to reduced platelet activation and consequently a lower risk of thrombosis.

2 December 2024
Verified
Other
Open access
HDHuan Dong
Huan Dong
JCJia Chen
Jia Chen
JZJing Zhang
Jing Zhang
FXFeng Xue
Feng Xue
HLHuiyuan Li
Huiyuan Li
LZLei Zhang
Lei Zhang
Supplementary Table S1. Basic characteristics of ET patients and healthy donors.

2 December 2024
Verified
Other
Open access
HDHuan Dong
Huan Dong
JCJia Chen
Jia Chen
JZJing Zhang
Jing Zhang
FXFeng Xue
Feng Xue
HLHuiyuan Li
Huiyuan Li
LZLei Zhang
Lei Zhang
Supplementary Table S2. Targeted 267-gene panel for next-generation sequencing.

2 December 2024
Verified
Other
Open access
HDHuan Dong
Huan Dong
JCJia Chen
Jia Chen
JZJing Zhang
Jing Zhang
FXFeng Xue
Feng Xue
HLHuiyuan Li
Huiyuan Li
LZLei Zhang
Lei Zhang
Supplementary Figure S1. Platelet CD62P expression in JAK2V617F-positive ET patients and TN-ET patients of different age groups.